← Back to Search

Other

LY3437943 for Obesity

Phase 1
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to week 17 (inclusive)
Awards & highlights

Study Summary

"This trial will compare a new drug to a placebo to see how it affects calorie intake, energy metabolism, and appetite. It will last up to 6 months and participants may have up to 20

Who is the study for?
This trial is for individuals with obesity, defined as having a BMI greater than 30 kg/m2. Participants should have tried at least one diet to lose weight without success. Specific details on who can't join are not provided.Check my eligibility
What is being tested?
The study is testing LY3437943 against a placebo to see its effects on how many calories participants eat, their energy use, and appetite levels. It involves up to 20 visits over a maximum of six months.See study design
What are the potential side effects?
Potential side effects of LY3437943 aren't detailed here, but common drug-related risks may include digestive issues, changes in appetite or metabolism, and possible reactions at the injection site if applicable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to week 17 (inclusive)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to week 17 (inclusive) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Secondary outcome measures
Change from Baseline in 24-hour EE
Change from Baseline in 24-hour Energy Expenditure (EE)
Change from Baseline in Fasting Appetite Visual Analog Score (VAS)
+4 more

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785
20%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3437943Experimental Treatment1 Intervention
LY3437943 administered subcutaneously (SC)
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~950

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,622 Previous Clinical Trials
3,216,701 Total Patients Enrolled
55 Trials studying Obesity
51,145 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,824 Total Patients Enrolled
38 Trials studying Obesity
30,864 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being sought for enrollment in this study?

"Yes, the details on clinicaltrials.gov demonstrate that this trial is actively seeking individuals to participate. The study was initially uploaded on March 20th, 2024, and most recently revised on April 18th of the same year. This research endeavor aims to enroll a total of 74 patients across three specific locations."

Answered by AI

Is the trial open to participants who are younger than 18 years old?

"To be eligible for enrollment, individuals must have surpassed 18 years of age but not reached 60 years."

Answered by AI

What is the total number of individuals currently enrolled in this research investigation?

"A minimum of 74 eligible participants must be enrolled to proceed with the clinical trial. The investigation, overseen by Eli Lilly and Company, will take place at various locations such as Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Columbia University Medical Center in New york City."

Answered by AI

Has LY3437943 received approval from the FDA?

"The safety rating for LY3437943 has been scored at 1 due to the ongoing Phase 1 trial, signifying scarce evidence backing its safety and effectiveness."

Answered by AI

Who else is applying?

What site did they apply to?
Pennington Biomedical Research Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
2024. "A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06313528.
All > Orlando > New Orleans
~49 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top